The initial antiretroviral regimen chosen for infected infants theoretically could be influenced by the antiretroviral regimen their mother may have received during pregnancy.
However, data from PACTG protocol 076 indicate that ZDV resistance did not account for most infants who became infected despite maternal ZDV treatment [73, 74], and data from PACTG protocol 185 indicate that duration of prior ZDV therapy in women with advanced HIV disease, many of whom received prolonged ZDV before pregnancy, was not associated with diminished ZDV efficacy for reduction of transmission [75].
Data do not suggest that the antiretroviral regimen for infected infants should routinely be chosen on the basis of maternal antiretroviral use.
Continue to monitor the frequency of antiretroviral-resistant virus among newly infected infants is important.